Home » Mobius Gets Orphan Drug Designation for Cornea Indication
Mobius Gets Orphan Drug Designation for Cornea Indication
Mobius Therapeutics, LLC… has received Orphan Drug Designation from the Food and Drug Administration for their platform product, Mitosol, for use in “Prevention of recurrence of pterygium after its surgical excision.”
FreshNews
FreshNews
Upcoming Events
-
07May
-
14May
-
30May